| Literature DB >> 26411363 |
C F de la Cruz-Herrera1, M Baz-Martínez2, V Lang3, A El Motiam2, J Barbazán4, R Couceiro4, M Abal4, A Vidal2, M Esteban1, C Muñoz-Fontela5, A Nieto1,6, M S Rodríguez3, M Collado4, C Rivas1,2.
Abstract
Class IA phosphatidylinositol 3-kinases (PI3Ks) are composed of p110 catalytic and p85 regulatory subunits. How regulatory subunits modulate PI3K activity remains only partially understood. Here we identified SUMO (small ubiquitin-related modifier) as a new player modulating this regulation. We demonstrate that both p85β and p85α are conjugated to SUMO1 and SUMO2. We identified two lysine residues located at the inter-SH2 domain on p85β, a critical region required for inhibition of p110, as being required for SUMO conjugation. A SUMOylation-defective mutant p85β shows higher activation of the PI3K pathway, and increased cell migration and transformation. Moreover, the cancer-related KS459del mutant in p85α was less efficiently SUMOylated compared with the wild-type protein. Finally, our results show that SUMO modulates p85 tyrosine phosphorylation, a modification correlating with PI3K pathway activation. Thus, SUMO reduces the levels of tyrosine-phosphorylated-p85 while loss of SUMOylation results in increased tyrosine phosphorylation of p85. In summary, we identify SUMO as a new important player in the regulation of the PI3K pathway through modulation of p85.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26411363 DOI: 10.1038/onc.2015.356
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867